<DOC>
	<DOCNO>NCT00703170</DOCNO>
	<brief_summary>Rationale : The Mammalian Target Rapamycin ( mTOR ) large polypeptide serine/threonine kinase 289 kDa ; kinases show important regulator cancer cell cycle , proliferation , invasion , angiogenesis , mTOR show key role signal malignant cell growth , proliferation , differentiation , migration , survival . Inhibition mTOR would result arrest cell growth G1 phase cell cycle . Temsirolimus ( CCI-779 ) soluble ester analogue rapamycin ( sirolimus ) show impressive vitro vivo cytostatic activity selectively inhibit mTOR . In animal model , temsirolimus demonstrate impressive cytostatic effect wide variety cancer cell . In vitro , inhibited growth human T-cell leukemia , glioblastoma , melanoma , prostate , breast , renal cell , pancreatic cell , show particular sensitivity temsirolimus , significant growth inhibition concentration less 0.01micrometer . In Phase I trial , temsirolimus investigate single agent weekly schedule well daily 5 day every week , evidence activity observe entire dose range ( 15 - 220 mg/m2 ) patient breast renal cancer . There apparent relationship exposure clinical benefit , suggest inhibition mTOR may achieve dos well dose level result dose limiting toxicity . Major tumor response note Phase I trials patient previously treat lung , breast , renal well neuroendocrine tumor . Minor response note soft tissue sarcoma , endometrial , cervical carcinoma . Pegylated liposomal doxorubicin FDA approve use refractory metastatic ovarian cancer AIDS-related Kaposi 's Sarcoma . It also show effective previously treat metastatic breast cancer . Combination study preclinical model suggest rapamycin analogue least additive effect standard chemotherapy radiation . In addition , study breast cancer cell line suggest mTOR inhibitor may reverse resistance anti-estrogen agent . Thus , propose combination temsirolimus liposomal doxorubicin highly effective metastatic solid tumor malignancy . Objectives : Primary - To define maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) temsirolimus combination pegylated liposomal doxorubicin patient resistant solid malignancy . - To determine incidence severity toxicity temsirolimus combination pegylated liposomal doxorubicin patient resistant solid malignancy . Secondary - To assess pharmacokinetic profile temsirolimus combination pegylated liposomal doxorubicin . - To determine anti-tumor activity response combination temsirolimus pegylated liposomal doxorubicin treatment patient resistant solid malignancy .</brief_summary>
	<brief_title>Phase I Study DOXIL Temsirolimus Resistant Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Patients must histologically cytologically proven solid malignancy resistant conventional therapy effective therapy know . Patients measurable nonmeasurable disease eligible entry study . In addition , patient without measurable nonmeasurable disease also eligible . Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . No chemotherapy radiotherapy may give within 4 week prior start protocol treatment . Patients must ≥18 year old . ECOG 02 study entry . Patients must life expectancy great 8 week . Required Laboratory Values : absolute neutrophil count ≥1,500/mm3 platelets ≥100,000/mm3 hemoglobin ≥9.0 g/dL total bilirubin ≤1.5 x ULN AST ( SGOT ) /ALT ( SGPT ) ≤1.5 x ULN ( ≤2.5 x ULN patient liver metastasis ) alkaline phosphatase ≤2.5 x ULN creatinine ≤1.5 x ULN OR creatinine clearance ≥60 mL/min/1.732 patient creatinine level 2.0 mg/dl serum cholesterol ≤350 mg/dL /9.0 mmol/L ( fast ) triglyceride ≤400 mg/dL ( fast ) * albumin ≥3.0 mg/dL PT/INR ≤1.5 , unless patient full dose warfarin stable dose LMW heparin therapeutic INR &gt; 1.5 ≤3 *Patients triglyceride level &gt; 400 mg/dL start lipid lower agent reevaluate within 1 week . If level go ≤400 mg/dL , consider trial continue lipid lowering agent . Temsirolimus primarily metabolize CYP3A4 . Patients receive enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer rifampin St. John 's wort , may decrease temsirolimus level . Patients know hypersensitivity reaction macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) eligible trial . Patients must normal leave ventricular ejection fraction ( LVEF ≥50 % ) MUGA scan . For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Pregnant nursing woman eligible . Patients receive antiretroviral therapy ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Patients must active CNS disease . Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Patients must sign Washington University , Human Research Protection Office ( HRPO ) approve informed consent . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>